医学
免疫疗法
疾病
肺癌
肿瘤科
癌症研究
癌症
内科学
作者
W. Jeffrey Petty,Luis Paz‐Ares
出处
期刊:JAMA Oncology
[American Medical Association]
日期:2022-12-15
卷期号:9 (3): 419-419
被引量:164
标识
DOI:10.1001/jamaoncol.2022.5631
摘要
Therapeutic optimization of SCLC remains a challenge, but recent trial results and drug approvals are encouraging. Advances in research have revealed critical information regarding biologic characteristics of the disease, which may lead to the identification of vulnerabilities and the development of new therapies. Further research focused on identifying biomarkers and evaluating innovative therapies will be paramount to improving treatment outcomes for patients with SCLC.
科研通智能强力驱动
Strongly Powered by AbleSci AI